Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s share price gapped up prior to trading on Thursday after Mizuho raised their price target on the stock from $205.00 to $250.00. The stock had previously closed at $128.60, but opened at $140.28. Mizuho currently has an outperform rating on the stock. Palvella Therapeutics shares last traded at $142.63, with a volume of 220,474 shares changing hands.

A number of other equities analysts have also recently issued reports on PVLA. Raymond James Financial restated a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Chardan Capital upped their target price on shares of Palvella Therapeutics from $174.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday. BTIG Research increased their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald lifted their price objective on Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $176.44.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 / late‑stage clinical news has driven investor enthusiasm — coverage and headlines about a late‑stage win for Palvella’s lead asset are cited as a major momentum driver. Palvella Therapeutics shares surge on positive Phase 3 trial results
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and bumped its price target to $255 (from $200), and the firm retains a Buy — analyst upgrades and a hawkish target boost sentiment and institutional interest. Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
• Positive Sentiment: Other firms have increased targets (Mizuho $250, BTIG $215, Chardan $210), signaling broad analyst conviction and adding buying pressure from funds tracking upgrades. Chardan Capital Boosts Palvella Therapeutics Price Target to $210.00
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise roughly $200M (plus a 30‑day option on 240k shares). The proceeds will fund QTORIN programs and R&D (cash runway positive), but the issuance dilutes current shareholders and adds near‑term supply. Palvella Therapeutics Announces Pricing of Upsized Public Offering
• Negative Sentiment: Short interest rose ~22% in February to about 1.67M shares (~17.8% of float) with ~5.5 days to cover; sizable short positions can pressure the stock if trial/clinical timelines slip, though they can also amplify rallies in the near term. Insider sales have also been reported, which some investors view negatively. (No single article link provided in the feed.)

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Archer Investment Corp bought a new position in Palvella Therapeutics in the 3rd quarter valued at $28,000. Group One Trading LLC raised its holdings in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Palvella Therapeutics in the third quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Palvella Therapeutics during the 2nd quarter worth about $37,000. Finally, JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares during the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Trading Up 15.3%

The stock has a market cap of $1.76 billion, a P/E ratio of -56.40 and a beta of -0.16. The business’s fifty day simple moving average is $93.82 and its 200 day simple moving average is $79.34.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.